Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 8/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL891809 | 0.83 | BACE1 (0.39) | BACE1CTSDAKR1B1AKR1A1APP | |
| SCHEMBL891983 | 0.83 | BACE1 (0.46) | BACE1CTSD | |
| SCHEMBL892115 | 0.80 | BACE1 (0.52) | BACE1CTSDAPP | |
| SCHEMBL10209440 | 0.76 | BACE1 (0.37) | BACE1CTSDAKR1B1AKR1A1APP | |
| SCHEMBL891714 | 0.75 | BACE1 (0.35) | BACE1CTSDAKR1B1AKR1A1APP | |
| SCHEMBL892285 | 0.75 | BACE1 (0.35) | BACE1CTSDAKR1B1AKR1A1APP | |
| SCHEMBL892228 | 0.75 | BACE1 (0.35) | BACE1CTSDAKR1B1AKR1A1APP | |
| SCHEMBL891705 | 0.75 | BACE1 (0.35) | BACE1CTSDAKR1B1AKR1A1APP | |
| SCHEMBL891721 | 0.75 | BACE1 (0.35) | BACE1CTSDAKR1B1AKR1A1APP | |
| SCHEMBL877046 | 0.74 | BACE1 (0.43) | BACE1CTSDAKR1B1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
| WO-2012040641-A2 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | BACE1 1/4885CTSD 224/4885AKR1B1 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.